Senti Biosciences Stock Price, News & Analysis (NASDAQ:SNTI) $0.44 +0.01 (+2.33%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.41▼$0.4550-Day Range$0.28▼$0.6852-Week Range$0.27▼$2.37Volume202,649 shsAverage Volume7.35 million shsMarket Capitalization$19.60 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Senti Biosciences MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside809.1% Upside$4.00 Price TargetShort InterestBearish5.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.59) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector634th out of 952 stocksBiological Products, Except Diagnostic Industry106th out of 164 stocks 3.2 Analyst's Opinion Consensus RatingSenti Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Senti Biosciences has a forecasted upside of 809.1% from its current price of $0.44.Amount of Analyst CoverageSenti Biosciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.71% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 260.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNTI. Previous Next 3.0 News and Social Media Coverage News SentimentSenti Biosciences has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Senti Biosciences this week, compared to 0 articles on an average week.Search Interest9 people have searched for SNTI on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows2 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.37% of the stock of Senti Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Senti Biosciences are expected to grow in the coming year, from ($1.59) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Senti Biosciences Stock (NASDAQ:SNTI)Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More SNTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNTI Stock News HeadlinesNovember 24, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 13, 2023 | finance.yahoo.comSenti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 11, 2023 | morningstar.comSenti Biosciences Inc SNTINovember 7, 2023 | msn.comWhy Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?November 7, 2023 | msn.comWhy Is Ventyx Biosciences (VTYX) Stock Down 76% Today?November 7, 2023 | msn.comWhy Is Senti Biosciences (SNTI) Stock Up 140% Today?November 6, 2023 | finance.yahoo.comSenti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in ChinaDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 31, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual MeetingOctober 9, 2023 | bizjournals.comGene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facilitySeptember 27, 2023 | investing.comShanti Overseas India Ltd (SNTI)September 27, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 MeetingSeptember 26, 2023 | finance.yahoo.comSenti Bio to Participate in Upcoming ConferencesAugust 15, 2023 | msn.comChardan Capital Reiterates Senti Biosciences (SNTI) Buy RecommendationAugust 11, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesAugust 11, 2023 | finance.yahoo.comSenti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesAugust 11, 2023 | finance.yahoo.comSenti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue EstimatesAugust 10, 2023 | finance.yahoo.comSenti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon PartnersJune 5, 2023 | finance.yahoo.comHere's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash WiselyMay 11, 2023 | msn.comChardan Capital Maintains Senti Biosciences (SNTI) Buy RecommendationMay 9, 2023 | finance.yahoo.comSenti Bio Announces First Quarter 2023 Results and Pipeline UpdatesMay 2, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual MeetingApril 17, 2023 | finance.yahoo.comSenti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR MeetingApril 14, 2023 | finance.yahoo.comSenti Bio to Participate in Upcoming Investor ConferencesMarch 24, 2023 | markets.businessinsider.comExpert Ratings for Senti BiosciencesMarch 24, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Hold Rating on Senti Biosciences (SNTI)See More Headlines Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNTI CUSIPN/A CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees122Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+809.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,210,000.00 Net Margins-2,692.82% Pretax Margin-3,609.96% Return on Equity-63.39% Return on Assets-43.10% Debt Debt-to-Equity RatioN/A Current Ratio7.81 Quick Ratio7.81 Sales & Book Value Annual Sales$4.29 million Price / Sales4.57 Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book0.24Miscellaneous Outstanding Shares44,540,000Free Float38,977,000Market Cap$19.60 million OptionableNot Optionable Beta2.51 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Timothy K. Lu M.D. (Age 42)Ph.D., Co-founder, CEO, President & Director Comp: $811.26kDr. James J. Collins Ph.D. (Age 57)Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director Comp: $41.49kDr. Deborah A. Knobelman Ph.D. (Age 49)CFO, Head of Corporate Development & Treasurer Comp: $600.22kMs. Susan D. Berland (Age 68)Senior Financial Executive & Independent Director Comp: $54.23kDr. Kanya Rajangam M.D. (Age 50)Ph.D., Head of Research & Development and Chief Medical Officer Comp: $679.71kDr. Wilson Wong Ph.D.Scientific Co-Founder & Member of Scientific Advisory BoardMr. Mike RheeSenior VP of Legal Affairs & Corporate SecretaryMr. Martin A. Giedlin Ph.D.Senior Vice President of Science DevelopmentSusan KahlertControllerMore ExecutivesKey CompetitorsPHAXIAM TherapeuticsNASDAQ:PHXMProtara TherapeuticsNASDAQ:TARAAptose BiosciencesNASDAQ:APTOBioCardiaNASDAQ:BCDAEiger BioPharmaceuticalsNASDAQ:EIGRView All CompetitorsInstitutional OwnershipTD Asset Management IncBought 113,172 shares on 10/27/2023Ownership: 0.542%Triatomic Management LPBought 89,650 shares on 9/7/2023Ownership: 0.675%View All Institutional Transactions SNTI Stock Analysis - Frequently Asked Questions Should I buy or sell Senti Biosciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SNTI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNTI, but not buy additional shares or sell existing shares. View SNTI analyst ratings or view top-rated stocks. What is Senti Biosciences' stock price target for 2024? 3 brokerages have issued 12 month target prices for Senti Biosciences' shares. Their SNTI share price targets range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 809.1% from the stock's current price. View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts. How have SNTI shares performed in 2023? Senti Biosciences' stock was trading at $1.41 at the beginning of 2023. Since then, SNTI stock has decreased by 68.8% and is now trading at $0.44. View the best growth stocks for 2023 here. Are investors shorting Senti Biosciences? Senti Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,500,000 shares, an increase of 260.1% from the October 31st total of 416,500 shares. Based on an average trading volume of 2,530,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 5.7% of the shares of the stock are short sold. View Senti Biosciences' Short Interest. When is Senti Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our SNTI earnings forecast. What ETF holds Senti Biosciences' stock ? ARK Genomic Revolution ETF holds 1,882,161 shares of SNTI stock, representing 0.08% of its portfolio. Who are Senti Biosciences' major shareholders? Senti Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include TD Asset Management Inc (0.54%). View institutional ownership trends. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SNTI) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.